European journal of obstetrics, gynecology, and reproductive biology · 2026
Outcomes of GnRH agonist trigger in dydrogesterone-based PPOS versus GnRH antagonist cycles: a retrospective parallel cohort in freeze-all IVF treatment.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Melado L, Ata B, Kalafat E, Del Gallego R, Bayram A, ElKhatib I, Lawrenz B, Fatemi H
Аннотация
PURPOSE: To compare laboratory and embryological outcomes between dydrogesterone-based progesterone-primed ovarian stimulation (PPOS) and GnRH antagonist cycles when a GnRH agonist is used for final oocyte maturation in freeze-all IVF treatment.
METHODS: This retrospective parallel cohort study included 795 stimulation cycles (718 antagonist, 77 PPOS) performed between May 2015 and September 2024 at ART Fertility Clinics UAE. All cycles used a GnRH agonist trigger (triptorelin 0.3 mg) for final oocyte maturation. The primary outcome was the number of mature (MII) oocytes retrieved. Secondary outcomes included fertilization rate, blastulation rate, blastocyst count, euploidy rate, oocyte retrieval rate (ORR), and follicular output index (FOI). Multivariable mixed-effects models adjusted for age, BMI, ovarian reserve parameters, stimulation medication, cycle type, and treatment center.
RESULTS: Patients in the PPOS and antagonist groups differed in age and BMI, while ovarian reserve markers were comparable. After adjustment for confounders, no statistically significant differences were observed between protocols in mature oocyte yield (IRR 1.00, p = 0.962), maturation rate (OR 0.94, p = 0.680), fertilization rate (OR 0.88, p = 0.384), blastocyst count (IRR 0.97, p = 0.773), blastulation rate (OR 1.10, p = 0.639), or euploidy rate (OR 1.06, p = 0.734). Maternal age remained the strongest predictor of euploidy.
CONCLUSIONS: Dydrogesterone-based PPOS demonstrated no statistically significant differences in oocyte, embryo, or genetic outcomes compared with GnRH antagonist cycles when a GnRH agonist trigger was used. These findings indicate that PPOS is a feasible alternative for freeze-all cycles requiring an agonist trigger, although larger prospective studies are needed to confirm equivalence.
METHODS: This retrospective parallel cohort study included 795 stimulation cycles (718 antagonist, 77 PPOS) performed between May 2015 and September 2024 at ART Fertility Clinics UAE. All cycles used a GnRH agonist trigger (triptorelin 0.3 mg) for final oocyte maturation. The primary outcome was the number of mature (MII) oocytes retrieved. Secondary outcomes included fertilization rate, blastulation rate, blastocyst count, euploidy rate, oocyte retrieval rate (ORR), and follicular output index (FOI). Multivariable mixed-effects models adjusted for age, BMI, ovarian reserve parameters, stimulation medication, cycle type, and treatment center.
RESULTS: Patients in the PPOS and antagonist groups differed in age and BMI, while ovarian reserve markers were comparable. After adjustment for confounders, no statistically significant differences were observed between protocols in mature oocyte yield (IRR 1.00, p = 0.962), maturation rate (OR 0.94, p = 0.680), fertilization rate (OR 0.88, p = 0.384), blastocyst count (IRR 0.97, p = 0.773), blastulation rate (OR 1.10, p = 0.639), or euploidy rate (OR 1.06, p = 0.734). Maternal age remained the strongest predictor of euploidy.
CONCLUSIONS: Dydrogesterone-based PPOS demonstrated no statistically significant differences in oocyte, embryo, or genetic outcomes compared with GnRH antagonist cycles when a GnRH agonist trigger was used. These findings indicate that PPOS is a feasible alternative for freeze-all cycles requiring an agonist trigger, although larger prospective studies are needed to confirm equivalence.